<DOC>
	<DOCNO>NCT00002579</DOCNO>
	<brief_summary>RATIONALE : Estrogen stimulate growth breast cancer cell . Hormone therapy use tamoxifen may fight breast cancer block uptake estrogen . Combining combination chemotherapy hormone therapy may kill tumor cell . PURPOSE : Randomized phase III trial compare effectiveness combination chemotherapy without tamoxifen treat woman stage I stage II breast cancer surgically remove .</brief_summary>
	<brief_title>Tamoxifen Following Combination Chemotherapy Treating Women With Operable Invasive Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess disease-free overall survival produce adjuvant tamoxifen give postoperative chemotherapy cyclophosphamide/methotrexate/fluorouracil ( CMF ) vs. adjuvant CMF alone woman primary breast cancer . OUTLINE : This randomize study . Patients stratified age participate institution . All patient undergo surgical resection local radiation therapy , appropriate . Within 4 week surgery , patient receive cyclophosphamide , methotrexate , fluorouracil ( CMF ) every 3 week 6 course . Radiotherapy give within 4 week completion CMF . Before begin last course CMF , patient randomize receive either oral tamoxifen daily 5 year therapy . Patients follow every 6 month 5 year , yearly . Hormone therapy prohibit except specify except short-term hormone replacement therapy severe unresponsive menopausal symptom . PROJECTED ACCRUAL : Approximately 2,000 patient require . Data patient enter Scotland part study pool data EORTC-10901 study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer palpable , unilateral , invasive disease Bilateral mammography require within 1 year prior randomization TNM Stage T13 , N01 , M0 disease adjuvant chemotherapy consider essential part initial therapy No prior pure situ carcinoma either breast No concurrent situ carcinoma No Paget 's disease nipple without underlie invasion No evidence distant disease , e.g . : No ipsilateral supraclavicular node enlargement unless proven benign Hormone receptor status : Any status PATIENT CHARACTERISTICS : Age : Not specify Sex : Women Menopausal status : Pre postmenopausal Performance status : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : No serious unrelated illness No prior invasive malignancy site except adequately treat nonmelanomatous skin cancer No pregnant nursing woman Adequate contraception require PRIOR CONCURRENT THERAPY : No prior tamoxifen currently receive tamoxifen</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
</DOC>